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The endocannabinoid system regulates some
aspects of the brain’s inflammatory response, includ-
ing the release of pro-inflammatory cytokines and
modulation of microglial activation.
1–4 The endo-
cannabinoid system is composed of two G-protein-
coupled receptors designated as CB1 and CB2
expressed throughout the body and notably by neural
stem cells.
5 We have previously shown that stimula-
tion of the CB1/2 receptors using a low dose of
WIN-55,212-2 significantly reversed the LPS-induced
microglia activation in young rats.
2 This anti-inflam-
matory effect was also found in aged rats, attenuating
the age-induced performance impairment observed in
the water pool task.
3 As normal aging is associated
with increased levels of microglial activation and a
decrease in neurogenesis, both probably contributing
to the hippocampus-related memory deficit, we
investigated the effects of an agonist of CB1/2
receptors on neurogenesis in the brain of normal
aged rats.
A total of 12 old (23-month-old) and 6 young
(3-month-old) male F-344 rats were chronically
infused for 28 days subcutaneously using an osmotic
minipump with WIN-55,212-2 (2mgkg
 1 per day
n=6) or the vehicle (n=12) into the dorsal abdominal
area. Two injections of 50mgkg
 1 i.p. of 5-bromo-2-
deoxyuridine were made on day 1 and day 2 post
surgery to track new cells’ production. The rats were
assigned to one of the following three groups: young-
vehicle (n=6), oldþvehicle (n=6) and oldþWIN-
55,212-2 2mgkg
 1 per day (n=6).
Doublecortin immunoreactivity was found only in
the subgranular zone of the dentate gyrus (DG) of the
hippocampus (Figure 1A). A significant difference
(Figure 1Aa–d) in doublecortin immunoreactivity was
found between young (3-month-old, 73.125±22.8
cells per DG) and old rats (23-month-old, 3±1.8
P<0.05). The 4 weeks of WIN 55,212-2 infusion
resulted in a significant increase in doublecortin
immunoreactivity cells (þ116%, F1,30=6.774,
P=0.0142, ANOVA with Fisher’s PLSD post-hoc test)
as compared with that in old vehicle-treated controls
(Figure 1B).
5-bromo-2-deoxyuridine immunoreactivity was
found sparsely in the cortex and hippocampus of
the old vehicle-treated controls. The number of 5-
bromo-2-deoxyuridine immunoreactivity cells was
counted in the DG; the 4 weeks of WIN-55,212-2
infusion produced a significant increase in 5-bromo-
2-deoxyuridine immunoreactivity cells (þ63%,
F1,221=12.795, P=0.0004 ANOVAwith Fisher’s PLSD
post-hoc test) as compared with that in old vehicle-
treated controls (Figure 1C). The proportion of newly
produced neurons over glial cells was determined
and showed no significant difference between control
or treated aged rats (Figure 1D, P=0.42), confirming
the increase in number of neurons engrafted in the DG
after the 4-week treatment.
Our results confirm that neurogenesis is still
present during normal aging in rats, although at a
drastically reduced level as compared with that in
young rats, for review see Verret et al.
6 We now report
that neurogenesis in aged rats can be significantly
increased by a low, continuous, non-psychoactive
dose of a cannabinoid receptor agonist, WIN-55,212-2.
This report shows for the first time the potential
therapeutic efficacy of endocannabinoid receptor
stimulation in stimulating neurogenesis from prolif-
eration to engraftment during normal aging in vivo.
The current results, coupled with our previous
observations regarding the role of endocannabinoid
receptors,
3,4 underscores the potential clinical bene-
fits of cannabinoid pharmacotherapies during normal
and pathological brain aging.
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Activation of brain
interleukin-1b in
schizophrenia
Molecular Psychiatry (2009) 14, 1069–1071; doi:10.1038/
mp.2009.52
The underlying pathophysiological cause of schizo-
phrenia is essentially unknown. Increasing evidence
suggests that immunological processes may contri-
bute to the etiology of the disease. Owing to the lack
of direct evidence of an infectious cause of schizo-
phrenia much attention has been directed towards
cytokines; molecules that initiate immunological
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level of cytokines in the serum of patients with
schizophrenia have provided an inconsistent picture
in this regard.
1 The relatively few studies focusing on
the level of cytokines in the cerebrospinal fluid (CSF)
have been limited to a restricted number of cytokines
analysed, to the lack of a control group of healthy
volunteers or to the sensitivity of the cytokine assays
used. Here, a sensitive assay was used to analyse the
CSF concentration of well-characterized cytokines in
first-episode patients with schizophrenia and age-
matched healthy volunteers.
Lumbar punctures were carried out on twenty-six
infection-free, first-episode male Caucasians who
later were diagnosed with schizophrenia (DSM-IV).
Patients were treated with various antipsychotics
from the day of hospitalization to lumbar puncture
(about three weeks). Thirty healthy male Caucasian
volunteers served as controls. Cytokines were
analysed using a sandwich-immunoassay-based
protein-array system, see Supplementary Materials.
Interleukin (IL)-1b, IL-6 and IL-8 were reliably
detectable in CSF of both patients and controls.
IL-2, IL-4, IL-5, IL-10, granulocyte–macrophage-
colony stimulating factor, interferon-g and tumour
necrosis factor-a were found in low concentrations
(median <0.5pg/ml) or were undetectable in both
patients and controls. In patients, IL-1b concentrations
were markedly elevated (median 4.37pg/ml) compared
with controls (median 0.78pg/ml; Figure 1). Analysis
of IL-6 and IL-8 showed no significant difference
between patients (median 2.53 and 64.6pg/ml, respec-
tively) and controls (median 2.52pg/ml and 89.0pg/
ml, respectively). No correlations were observed
between cytokine concentrations and age, smoking or
length/dosage of antipsychotic medication.
These results provide evidence for the activation of
the brain immune system in first-episode schizophre-
nia. This is in contrast to previous studies examining
CSF of chronic patients with regard to IL-1b.
2
Possibly, the elevation of IL-1b may be normalized
or downregulated along the disease progress or during
prolonged antipsychotic treatment. Whether the
elevation of IL-1b is congenital, acquired during
prodromal phase or absent until the time of first
psychotic episode remains to be elucidated.
Like other cytokines, IL-1b is released from micro-
glia and astrocytes. However, as serum cytokines may
access brain for example, through saturable carriers or
a damaged blood brain barrier,
3 a peripheral contribu-
tion to CSF IL-1b levels should not be excluded. It
should be noted that the selective elevation of IL-1b
observed differs from the general activation of pro-
inflammatory cytokines seen during a CNS infection
and from the typical cytokine profile observed during
an autoimmune response.
During infection, pro-inflammatory cytokines, in-
cluding IL-1b are suggested to induce sickness beha-
viour for example, lethargy, anhedonia, cognitive
impairment and social withdrawal.
4 Similar symptoms
are also referred to as negative symptoms and cognitive
deficits in schizophrenia. Schizophrenia is generally
attributed to a dysfunction of brain dopaminergic and
glutamatergic circuits. Interestingly, administration of
IL-1b to rats is associated with an increased and
decreased dopamine concentration in the nucleus
accumbens
5 and prefrontal cortex, respectively,
6 con-
ditions proposed to occur simultaneously in schizo-
phrenia. With respect to glutamate neurotransmission
the action of IL-1b seems complex and diversified,
including both excitatory and inhibitory components.
These involve direct actions on the intercellular brain
signalling
7 as well as effects with delayed onset, like
altered expression of genes encoding the enzymes
regulating glutamate neurotransmission.
8 Clearly,
IL-1b possesses properties possibly causing a dopami-
nergic and glutamatergic dysregulation as proposed to
occur in schizophrenia.
This is the first study showing a marked elevation
of IL-1b in CSF of male patients with first-episode
schizophrenia. Regardless of whether such activation
of the brain immune system is of infectious, genetic or
other origin it is clearly associated with the onset of
schizophrenia. Present data are interesting in view
of genetic studies showing an association of poly-
morphisms in the IL-1 gene cluster in schizophre-
nia.
9,10 Our results may open up new therapeutic
strategies in the treatment of the disease. However,
it remains to be established if the activation of IL-1b
is causally related to the development of schizophre-
nia or is tentatively a consequence of the dopaminer-
gic/glutamatergic dysfunctions that characterize the
disease.
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Figure 1 Interleukin (IL)-1b in cerebrospinal fluid from
healthy volunteers (mean age 25.4±7.2 years) and patients
with schizophrenia (mean age 27.5±6.6 years). Each point
represents the concentration of IL-1b (pg/ml) in a single
cerebrospinal fluid (CSF) sample. Horizontal lines show
median values for each group. The 75 percentiles are 0.97
(healthy volunteers) and 12.2 (patients with schizophrenia).
P<0.0001 (Mann–Whitney U-test).
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